Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, gives his thoughts on practice-changing data from the recent ESMO 2021 meeting. Prof. Jones highlights data from the STAMPEDE (NCT00268476), PEACE-1 (NCT01957436), ARCHES (NCT02677896) and VISION studies (NCT03511664). Results from the STAMPEDE trial showed that following 2 years of abiraterone acetate plus prednisolone-based therapy, metastasis-free survival (MFS) was significantly improved and survival in patients with high-risk non-metastatic prostate cancer starting androgen deprivation therapy (ADT), and should be considered a new standard of care. Updates at ESMO 2021 from the PEACE-1 study reported that adding abiraterone to ADT plus docetaxel improves both radiographic progression-free survival (rPFS) and overall survival patients with de novo metastatic castration-sensitive prostate cancer (mCSPC). Data from the ARCHES trial (NCT02677896) showed that enzalutamide plus ADT prolongs survival in men with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, data presented at ESMO 2021 from the VISION study, reported that 177Lu-PSMA-617 plus standard of care (SOC) was generally well tolerated and delayed time to health-related quality of life (HRQoL) and pain worsening versus SOC alone in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This interview took place at the BOPA 2021 virtual meeting.